CO2017012835A2 - Neoantígenos compartidos - Google Patents
Neoantígenos compartidosInfo
- Publication number
- CO2017012835A2 CO2017012835A2 CONC2017/0012835A CO2017012835A CO2017012835A2 CO 2017012835 A2 CO2017012835 A2 CO 2017012835A2 CO 2017012835 A CO2017012835 A CO 2017012835A CO 2017012835 A2 CO2017012835 A2 CO 2017012835A2
- Authority
- CO
- Colombia
- Prior art keywords
- tumor
- subjects
- specific
- population
- neoantigenic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN DE LA DIVULGACIÓN Se divulga aquí en un aspecto una composición farmacéutica que comprende una pluralidad de péptidos neoantigénicos y un portador farmacéuticamente aceptable, cada péptido neoantigénico que comprende un neoepítopo específico a tumor capaz de unirse a una proteína HLA en un sujeto, cada neoepítopo específico a tumor comprende una mutación específica a tumor presente en un tumor, en el que (a) la composición comprende péptidos neoantigénicos que comprenden mutaciones específicas a tumor presente en por lo menos 1% de lo sujetos en una población de sujetos que sufren de cáncer; (b) la composición comprende péptidos neoantigénicos que comprenden neoepítopos específicos a tumores que se unen a proteínas HLA presentes en por lo menos 5% de lo sujetos en la población; y (c) la composición comprende por lo menos un péptido neoantigénico capaz de provocar una respuesta inmunitaria contra un tumor presente en por lo menos 5% de los sujetos en la población de sujetos que sufren de cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562179877P | 2015-05-20 | 2015-05-20 | |
US201662389377P | 2016-02-23 | 2016-02-23 | |
PCT/US2016/033452 WO2016187508A2 (en) | 2015-05-20 | 2016-05-20 | Shared neoantigens |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017012835A2 true CO2017012835A2 (es) | 2018-05-10 |
Family
ID=56203902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0012835A CO2017012835A2 (es) | 2015-05-20 | 2017-12-13 | Neoantígenos compartidos |
Country Status (21)
Country | Link |
---|---|
US (2) | US10835585B2 (es) |
EP (1) | EP3297660A2 (es) |
JP (3) | JP6913032B2 (es) |
KR (1) | KR20180010229A (es) |
CN (2) | CN116196401A (es) |
AU (2) | AU2016264623B2 (es) |
BR (1) | BR112017024797A2 (es) |
CA (1) | CA2986235A1 (es) |
CL (2) | CL2017002945A1 (es) |
CO (1) | CO2017012835A2 (es) |
CR (3) | CR20170584A (es) |
EC (1) | ECSP17084137A (es) |
HK (2) | HK1251148A1 (es) |
IL (3) | IL255769B2 (es) |
MX (2) | MX2017014700A (es) |
MY (1) | MY190974A (es) |
PE (1) | PE20180670A1 (es) |
PH (1) | PH12017502321A1 (es) |
RU (2) | RU2020132040A (es) |
TW (2) | TWI806815B (es) |
WO (1) | WO2016187508A2 (es) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
EP3405209B1 (en) * | 2016-01-19 | 2021-05-26 | The University Of Western Australia | Novel biomolecule conjugates and uses therefor |
US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
CN109563521A (zh) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
KR20180129899A (ko) * | 2016-03-31 | 2018-12-05 | 네온 테라퓨틱스, 인크. | 신생항원 및 이것의 사용 방법 |
UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017177207A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
UA127826C2 (uk) | 2016-05-18 | 2024-01-17 | Локсо Онколоджі, Інк. | СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
WO2018102613A2 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
BR112018015871B1 (pt) | 2016-12-09 | 2021-12-07 | The Broad Institute, Inc. | Sistema, método e dispositivo para detectar a presença de uma sequência alvo de ácido nucleico em uma amostra |
US11634486B2 (en) | 2016-12-23 | 2023-04-25 | Bluefin Biomedicine, Inc. | Anti-SEZ6L2 antibodies and antibody drug conjugates |
CA3049698A1 (en) * | 2017-01-13 | 2018-07-19 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
ES2971298T3 (es) * | 2017-01-18 | 2024-06-04 | Icahn School Med Mount Sinai | Neoantígenos y usos de los mismos para el tratamiento del cáncer |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CN110430894A (zh) | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
EP3576764A4 (en) * | 2017-02-03 | 2020-12-16 | The Medical College of Wisconsin, Inc. | KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE |
CN106868133A (zh) * | 2017-02-24 | 2017-06-20 | 北京致成生物医学科技有限公司 | 一种监测肿瘤发生发展的产品及其应用 |
US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
BR112019019087A2 (pt) | 2017-03-15 | 2020-05-12 | The Broad Institute, Inc. | Diagnóstico baseado em sistema efetor de crispr para detecção de vírus |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CN108659114B (zh) * | 2017-04-01 | 2022-10-21 | 中国科学院广州生物医药与健康研究院 | 识别pasd1抗原短肽的tcr |
AU2018258119B2 (en) | 2017-04-24 | 2021-04-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
AU2018266705B2 (en) | 2017-05-08 | 2023-05-04 | Gritstone Bio, Inc. | Alphavirus neoantigen vectors |
US20200061112A1 (en) * | 2017-05-10 | 2020-02-27 | University Of Connecticut | Dendritic Cells as a Novel Delivery System for Immunotherapy |
CN111406068A (zh) * | 2017-05-16 | 2020-07-10 | 约翰霍普金斯大学 | MANAbody及使用方法 |
IL271558B2 (en) | 2017-06-21 | 2024-01-01 | Transgene | A vaccine tailored to the individual |
US20200140813A1 (en) * | 2017-06-22 | 2020-05-07 | Tcer Ab | T-cell expansion method and uses |
WO2019004831A1 (en) * | 2017-06-30 | 2019-01-03 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
CN107188955A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用 |
CN107325171A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用 |
JP7274223B2 (ja) * | 2017-07-12 | 2023-05-16 | ノイスコム アーゲー | マイクロサテライト不安定性(msi)癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン |
JP7364237B2 (ja) | 2017-08-10 | 2023-10-18 | グッド ティー セルズ、 インコーポレイテッド | 癌治療のためのt細胞の活性化方法 |
CN111315390A (zh) * | 2017-09-05 | 2020-06-19 | 磨石肿瘤生物技术公司 | 用于t细胞疗法的新抗原鉴别 |
US11203615B2 (en) | 2017-09-11 | 2021-12-21 | National University Corporation Hokkaido University | Cancer treatment drug |
WO2019067243A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T CELL RECEPTORS RECOGNIZING P53 MUTE |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
BR112020015093A2 (pt) | 2018-01-29 | 2020-12-08 | The Broad Institute, Inc. | Diagnóstico baseado no sistema de efetor crispr |
JP6857930B2 (ja) * | 2018-02-15 | 2021-04-14 | 国立大学法人旭川医科大学 | がん抗原ペプチド |
US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
CN108588201B (zh) * | 2018-05-11 | 2019-08-09 | 浙江省人民医院 | 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置 |
WO2019217837A1 (en) * | 2018-05-11 | 2019-11-14 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
CN112899350B (zh) * | 2018-05-14 | 2023-01-24 | 北京艾克伦医疗科技有限公司 | 核酸检测方法和试剂盒 |
CN112261947A (zh) * | 2018-05-25 | 2021-01-22 | 威斯塔研究所 | 肿瘤特异性新抗原和其使用方法 |
CN108728529B (zh) * | 2018-06-06 | 2020-08-04 | 青岛泱深生物医药有限公司 | Znf770基因在制备诊治子痫前期的产品中的应用 |
CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
CN109142729B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-hmgb3自身抗体及其应用 |
CA3103181A1 (en) * | 2018-06-18 | 2019-12-26 | College De France | Ligand controling interaction between gags with their effector molecules and use thereof |
US20210268091A1 (en) * | 2018-06-19 | 2021-09-02 | Biontech Us Inc. | Neoantigens and uses thereof |
KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
GB201810358D0 (en) * | 2018-06-25 | 2018-08-08 | Univ College Cardiff Consultants Ltd | Cancer-specific t-cell receptors |
CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
US20210213116A1 (en) | 2018-07-26 | 2021-07-15 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
WO2020022902A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
US20210252123A1 (en) | 2018-07-26 | 2021-08-19 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
US20220160870A1 (en) * | 2018-08-28 | 2022-05-26 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
CA3109430A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
CN109022585A (zh) * | 2018-09-10 | 2018-12-18 | 路君 | Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用 |
BR112021005246A2 (pt) * | 2018-09-20 | 2021-06-15 | Daiichi Sankyo Company, Limited | agente terapêutico, e, método de tratamento para câncer |
CN109207431B (zh) * | 2018-10-12 | 2021-10-15 | 武汉大学 | 一种抑制人癌基因STAT3的α亚型表达的方法 |
CN109486935A (zh) * | 2018-10-18 | 2019-03-19 | 中国医学科学院北京协和医院 | 作为骨质疏松症诊治靶标的aknad1基因 |
CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
WO2020092705A1 (en) * | 2018-10-31 | 2020-05-07 | University Of Virginia Patent Foundation | Self-assembling peptides and hydrogels |
WO2020092998A1 (en) * | 2018-11-01 | 2020-05-07 | The Broad Institute, Inc. | Identification of pde3 modulator responsive cancers |
CN109504771A (zh) * | 2018-11-19 | 2019-03-22 | 北京大学深圳医院(北京大学深圳临床医学院) | Adcy2作为乳腺癌的分子标记物的应用 |
CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷(海南)生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
CN109371026A (zh) * | 2018-12-11 | 2019-02-22 | 宁夏医科大学总医院 | 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用 |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CN111363816B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于pax3和zic4基因的肺癌诊断试剂及试剂盒 |
CN109576362B (zh) * | 2018-12-28 | 2020-09-04 | 青岛泱深生物医药有限公司 | 阿尔茨海默诊治用标志物fam170a |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
JP2022522965A (ja) * | 2019-01-15 | 2022-04-21 | コーネル ユニバーシティー | 組換えラブリシン、並びにそれを使用するための組成物及び方法 |
CN112675297B (zh) * | 2019-01-29 | 2022-06-24 | 杭州纽安津生物科技有限公司 | 针对靶向药物阿比特龙、恩扎鲁胺、氟他胺、酮康唑聚的多肽疫苗组合及其设计方法 |
WO2020168047A1 (en) * | 2019-02-13 | 2020-08-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene |
CN113795263A (zh) | 2019-02-20 | 2021-12-14 | 鲁比厄斯治疗法股份有限公司 | 包含可负载抗原呈递多肽的工程化红系细胞及使用方法 |
CN109735624A (zh) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | 基因标志物在甲状腺癌诊断中的应用 |
EP3941932A1 (en) * | 2019-03-21 | 2022-01-26 | Institute for Research in Biomedicine | Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof |
IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
CN114127290A (zh) * | 2019-05-23 | 2022-03-01 | 克里斯蒂安娜保健服务公司 | 用于治疗癌症的变体nrf2的基因敲除 |
CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
US11306122B2 (en) * | 2019-06-14 | 2022-04-19 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor |
CA3144054A1 (en) * | 2019-06-20 | 2020-12-24 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
CN110358831B (zh) * | 2019-07-11 | 2021-12-24 | 江苏医药职业学院 | 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒 |
WO2021011417A1 (en) * | 2019-07-12 | 2021-01-21 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
MX2022000671A (es) * | 2019-07-16 | 2022-04-18 | Washington University St Louis | Anticuerpos anti-grp78 y metodo de uso de los mismos. |
US20220265792A1 (en) * | 2019-07-30 | 2022-08-25 | Breakbio Corp. | Methods for treating solid tumors |
CN114222588A (zh) | 2019-08-12 | 2022-03-22 | 雷杰纳荣制药公司 | 巨噬细胞刺激1受体(mst1r)变体及其用途 |
CN112402612B (zh) * | 2019-08-21 | 2023-05-26 | 苏州蓝马医疗技术有限公司 | 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法 |
EP4055059A4 (en) * | 2019-11-06 | 2024-01-10 | Ohio State Innovation Foundation | TARGETING CIRCULAR PCMTD1 IN LEUKEMIA WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS |
AU2020384374A1 (en) * | 2019-11-15 | 2022-06-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared neoantigens |
AU2020415375A1 (en) | 2019-12-23 | 2022-06-30 | The Regents Of The University Of California | Stabilization of MHC complexes |
CN113117081A (zh) * | 2019-12-30 | 2021-07-16 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
JP2023508726A (ja) * | 2019-12-31 | 2023-03-03 | エリクサージェン セラピューティクス,インコーポレイティド | 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達 |
CN111116728B (zh) * | 2020-01-13 | 2021-04-27 | 郑州大学 | 肿瘤特异性抗原ctl表位肽及其应用 |
JP2023511189A (ja) * | 2020-01-21 | 2023-03-16 | 上海柏全生物科技有限公司 | Semg2抗体およびその使用 |
WO2021168355A1 (en) * | 2020-02-20 | 2021-08-26 | Gritstone Bio, Inc. | Antigen-binding proteins targeting kklc-1 shared antigen |
CN111303268B (zh) * | 2020-03-10 | 2021-08-27 | 江苏兰恩生物治疗技术研究院有限公司 | 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗 |
CN113388023A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
CN113817740A (zh) * | 2020-06-19 | 2021-12-21 | 中国科学院化学研究所 | 一种核酸适配体识别并结合ptprf及其相关功能的应用研究 |
CN111718405B (zh) * | 2020-06-30 | 2022-09-13 | 青岛海兰深生物科技有限公司 | 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法 |
EP4176076A4 (en) * | 2020-07-02 | 2024-05-01 | Univ Johns Hopkins | METHYLATED MARKERS FOR THE ACCURATE DETECTION OF PRIMARY CENTRAL NERVOUS SYSTEM AND SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇iv及/或viii的經生物工程改造之t細胞介導之免疫力、材料、及其他方法 |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
JP2023551204A (ja) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
US20220194999A1 (en) * | 2020-12-23 | 2022-06-23 | Janssen Biotech, Inc. | Neoantigen Peptide Mimics |
CN112666358A (zh) * | 2021-01-14 | 2021-04-16 | 深圳裕康医学检验实验室 | 一种使用外周血检测抗原免疫原性的方法 |
CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
AU2022240549A1 (en) * | 2021-03-16 | 2023-10-05 | Shanghai Biotroy Biotechnique Co., Ltd | Semenogelin neutralizing antibody and epitope and application thereof |
CN113321720B (zh) * | 2021-03-24 | 2022-03-01 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
CN113321724B (zh) * | 2021-03-24 | 2022-02-01 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽及其应用 |
CN113896781A (zh) * | 2021-03-24 | 2022-01-07 | 深圳市新靶向生物科技有限公司 | 一种与肺癌驱动基因突变相关的抗原肽及其应用 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
IL282814A (en) * | 2021-04-29 | 2022-11-01 | Yeda Res & Dev | T-cell receptors against recurrent ras-derived neoantigens |
AU2022267777A1 (en) | 2021-04-30 | 2023-10-05 | Centre Hospitalier Universitaire Vaudois (Chuv) | Single vessel expansion of lymphocytes |
CN113527464A (zh) * | 2021-07-19 | 2021-10-22 | 新景智源生物科技(苏州)有限公司 | 识别mboat2的tcr |
CN113721030B (zh) * | 2021-08-30 | 2024-02-13 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
CN114085282A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用 |
CN114085281A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤抗原表位肽及其多聚体和应用 |
WO2023081655A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation |
KR20230068628A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
KR20230068627A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
CN114177274A (zh) * | 2021-12-13 | 2022-03-15 | 中国医学科学院微循环研究所 | Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物 |
WO2023114430A1 (en) * | 2021-12-16 | 2023-06-22 | The Johns Hopkins University | Manabodies targeting p53 tumor antigens and methods of using |
KR20230101285A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101287A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101284A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101283A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101286A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
WO2023150788A2 (en) * | 2022-02-07 | 2023-08-10 | Ubiquitx | Beta-catenin protein degradation |
CN114524872A (zh) * | 2022-03-09 | 2022-05-24 | 广州诺诚生物技术研发有限公司 | 一种用于乳腺癌检测的单克隆抗体及其试剂盒 |
CN115327125A (zh) * | 2022-07-14 | 2022-11-11 | 宁波大学 | 一种蛋白质inf2在制备肝癌诊断标志物中的应用 |
CN117586344A (zh) * | 2022-08-12 | 2024-02-23 | 上海交通大学医学院附属瑞金医院 | 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用 |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
WO2024097864A1 (en) | 2022-11-02 | 2024-05-10 | Tigen Pharma Sa | Expansion of lymphocytes |
EP4368189A1 (en) * | 2022-11-09 | 2024-05-15 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms |
CN116948004B (zh) * | 2023-09-13 | 2023-11-21 | 成都朗谷生物科技股份有限公司 | 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用 |
CN117567591B (zh) * | 2024-01-11 | 2024-04-26 | 中国人民解放军总医院 | 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用 |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
CA2005291C (en) | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
ATE157012T1 (de) | 1989-11-03 | 1997-09-15 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
WO1992014486A1 (en) | 1991-02-22 | 1992-09-03 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE | Transmission blocking vaccine against malaria |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
WO2001000225A1 (en) | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
EP0758397B1 (en) | 1994-04-29 | 2005-06-22 | Baxter Healthcare S.A. | Recombinant poxviruses with foreign polynucleotides in essential regions |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
IL129017A0 (en) | 1996-10-17 | 2000-02-17 | Oxford Biomedica Ltd | Retroviral vectors |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998040510A1 (en) | 1997-03-11 | 1998-09-17 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
US6638534B1 (en) | 1998-07-28 | 2003-10-28 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
WO2000020587A2 (en) | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
CA2374597A1 (en) | 1999-05-28 | 2000-12-07 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders |
US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
EP1250351B1 (en) | 2000-01-28 | 2005-11-30 | Statens Serum Institut | Methods to identify ctl epitopes of hiv |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
DE60130435T2 (de) | 2000-02-24 | 2009-07-23 | Invitrogen Corp., Carlsbad | Gleichzeitige stimulation und konzentration von zellen |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
PL205922B1 (pl) | 2000-03-14 | 2010-06-30 | Bavarian Nordic As | Zmodyfikowany wirus Ankara (MVA), zakażona nim komórka gospodarza, jego zastosowania, kompozycja farmaceutyczna i sposoby otrzymywania wirusa oraz sekwencji kwasu nukleinowego, peptydu i/lub polipeptydu |
US6686184B1 (en) | 2000-05-25 | 2004-02-03 | President And Fellows Of Harvard College | Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks |
GB0024550D0 (es) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US6923973B1 (en) | 2001-02-22 | 2005-08-02 | Board Of Regents, The University Of Texas System | Peptide and DNA immunization against Coccidioides immitis infections |
US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
ES2239246T3 (es) | 2001-08-31 | 2005-09-16 | Avidex Limited | Receptor soluble de celulas t. |
ES2532757T3 (es) | 2001-09-06 | 2015-03-31 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US7670781B2 (en) | 2002-01-03 | 2010-03-02 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal |
IL164287A0 (en) | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
NZ536592A (en) | 2002-04-19 | 2007-01-26 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
EP1551437A4 (en) | 2002-06-05 | 2006-03-29 | Univ Case Western Reserve | METHOD AND COMPOSITIONS FOR DETECTING CANCER |
ES2370688T3 (es) | 2002-06-13 | 2011-12-21 | Merck Patent Gmbh | Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante. |
JP2006507921A (ja) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 流体分散のための方法および装置 |
GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
US7378384B2 (en) | 2002-09-20 | 2008-05-27 | International Institute Of Cancer Immunology, Inc. | WT1 substitution peptides |
US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
WO2004058801A2 (en) | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
CA2521862C (en) | 2003-04-10 | 2012-10-16 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US20080274129A1 (en) | 2003-04-18 | 2008-11-06 | Fikes John D | Hla-A2 Tumor Associated Antigen Peptides and Compositions |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
US7371395B2 (en) | 2003-07-24 | 2008-05-13 | Merial Limited | Vaccine formulations |
EP2662136A3 (en) | 2003-08-27 | 2013-12-25 | President and Fellows of Harvard College | Method for handling and mixing droplets |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
US7084247B2 (en) | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
EP1765860B1 (en) | 2004-05-19 | 2008-12-10 | MediGene Ltd. | High affinity ny-eso t cell receptor |
JP4972549B2 (ja) | 2004-05-19 | 2012-07-11 | イムノコア リミテッド | T細胞レセプターを改善する方法 |
US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Cmv/r核酸コンストラクトを含むaidsに対するワクチン |
US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
WO2006089001A2 (en) | 2005-02-16 | 2006-08-24 | Lentigen Corporation | Lentiviral vectors and their use |
US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
US9039273B2 (en) | 2005-03-04 | 2015-05-26 | President And Fellows Of Harvard College | Method and apparatus for forming multiple emulsions |
AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
US20090142363A1 (en) | 2005-08-03 | 2009-06-04 | Medical And Biological Laboratories, Co., Ltd. | Cytotoxic t-cell epitope peptide and use thereof |
LT2578685T (lt) | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
US20070112754A1 (en) | 2005-11-15 | 2007-05-17 | Honeywell International Inc. | Method and apparatus for identifying data of interest in a database |
EP1984738A2 (en) | 2006-01-11 | 2008-10-29 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
ATE484335T1 (de) | 2006-01-27 | 2010-10-15 | Harvard College | Koaleszenz fluider tröpfchen |
US8793895B2 (en) | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
WO2007101227A2 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2530167A1 (en) | 2006-05-11 | 2012-12-05 | Raindance Technologies, Inc. | Microfluidic Devices |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP2390363A1 (en) | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals s.a. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the PRF1 gene |
US20100035973A1 (en) | 2006-07-17 | 2010-02-11 | Nationwide Children's Hospital, Inc. | Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines |
WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
JP5239041B2 (ja) | 2007-02-07 | 2013-07-17 | 一般財団法人阪大微生物病研究会 | 癌の治療剤 |
US20100099090A1 (en) | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
EP2829282B1 (en) | 2007-03-22 | 2017-10-25 | The Regents of The University of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
EP2155780B1 (en) | 2007-05-31 | 2013-02-27 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | P53 peptide vaccine |
JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール, インコーポレイテッド | Gitr結合分子を使用する併用療法 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
AU2008296733B2 (en) | 2007-08-08 | 2013-07-11 | The Board Of Regents Of The University Of Texas System | VEGFR-1/NRP-1 targeting peptides |
WO2009043520A1 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
CN104906597B (zh) | 2007-10-25 | 2018-07-10 | 东丽株式会社 | 免疫诱导剂 |
AU2008345036A1 (en) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer |
JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
US20110097312A1 (en) | 2008-02-15 | 2011-04-28 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
EP2274437B1 (en) | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
EP2331680B1 (en) | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
MX2011004050A (es) | 2008-10-17 | 2011-05-10 | Genentech Inc | Metodo de tratamiento. |
US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US8697854B2 (en) | 2008-11-24 | 2014-04-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
CA2756238A1 (en) | 2009-04-02 | 2010-10-07 | Vaxon Biotech | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
JP2013509170A (ja) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | アルブミン変異体 |
EP2509583B1 (en) | 2009-12-10 | 2019-05-15 | Merck Patent GmbH | Pharmaceutical composition comprising oligopeptides, preferably cilengitide |
US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
ES2788863T3 (es) | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
JP5965392B2 (ja) | 2010-05-28 | 2016-08-03 | オックスフォード バイオメディカ (ユーケー) リミテッド | 脳へのレンチウイルスベクターの送達 |
RU2621640C2 (ru) | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
CA2809362C (en) | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
WO2012095639A2 (en) | 2011-01-14 | 2012-07-19 | Genefirst Limited | Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence |
EP2478915A1 (en) | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
EP3859011A1 (en) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
BR112013029834A8 (pt) | 2011-05-24 | 2022-10-18 | Biontech Ag | vacinas individualizadas para câncer |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
JP2014526892A (ja) | 2011-08-18 | 2014-10-09 | ネステク ソシエテ アノニム | 対立遺伝子多型を検出するための組成物及び方法 |
CN103987396A (zh) | 2011-09-06 | 2014-08-13 | 新加坡科技研究局 | 多肽疫苗 |
SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
EP2755487B1 (en) | 2011-09-16 | 2018-12-19 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
WO2013086464A1 (en) | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
US20130210014A1 (en) | 2012-02-10 | 2013-08-15 | Jeff Sharman | Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients |
WO2013123031A2 (en) | 2012-02-15 | 2013-08-22 | Veridex, Llc | Highly sensitive method for detecting low frequency mutations |
US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
DK2844282T3 (da) | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
EP2850102A1 (en) | 2012-05-15 | 2015-03-25 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
IN2014DN10991A (es) | 2012-05-25 | 2015-09-25 | Cellectis | |
AU2013273987B2 (en) | 2012-06-15 | 2018-08-09 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
PL2872646T3 (pl) | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
CN104662171B (zh) | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
CN104507537A (zh) | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
JP6433894B2 (ja) | 2012-07-27 | 2018-12-05 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | T細胞受容体の操作 |
CA2883569A1 (en) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
EP2898096B1 (en) | 2012-09-21 | 2024-02-14 | The Broad Institute, Inc. | Methods for labeling of rnas |
CA2886684C (en) | 2012-10-10 | 2023-09-19 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2014056986A1 (en) | 2012-10-11 | 2014-04-17 | Universitat De Barcelona | Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll) |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
EP2925447B1 (en) | 2012-11-30 | 2020-04-08 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
EP2953958B1 (en) | 2013-02-07 | 2018-04-11 | Rutgers, the State University of New Jersey | Highly selective nucleic acid amplification primers |
MX2015011095A (es) | 2013-02-26 | 2016-03-11 | Sloan Kettering Inst Cancer | Composiciones y metodos para inmunoterapia. |
WO2014133568A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
US10176294B2 (en) | 2013-03-15 | 2019-01-08 | The Broad Institute, Inc. | Accurate typing of HLA through exome sequencing |
WO2014168874A2 (en) | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
US20160215042A1 (en) | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
EP3004877A4 (en) * | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
CA2932798C (en) | 2013-12-06 | 2022-09-20 | The Broad Institute, Inc. | Formulations for neoplasia vaccines |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
EP3152569B1 (en) | 2014-06-05 | 2020-06-10 | AIMM Therapeutics B.V. | Means and methods for determining t cell recognition |
JP6770957B2 (ja) | 2014-08-07 | 2020-10-21 | ファーマシスト リミテッドPharmassist Ltd | 試料中のpik3ca突然変異状態を決定する方法 |
EP3198031A1 (en) | 2014-09-22 | 2017-08-02 | Dana Farber Cancer Institute, Inc. | Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
CA2987730C (en) * | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
JP7236216B2 (ja) * | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
US20180127803A1 (en) | 2015-05-10 | 2018-05-10 | Quandx Inc. | Ultra sensitive probes for detection of nucleic acid |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
KR20180129899A (ko) | 2016-03-31 | 2018-12-05 | 네온 테라퓨틱스, 인크. | 신생항원 및 이것의 사용 방법 |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
-
2016
- 2016-05-20 TW TW105115840A patent/TWI806815B/zh active
- 2016-05-20 BR BR112017024797-6A patent/BR112017024797A2/pt active Search and Examination
- 2016-05-20 RU RU2020132040A patent/RU2020132040A/ru unknown
- 2016-05-20 WO PCT/US2016/033452 patent/WO2016187508A2/en active Application Filing
- 2016-05-20 PE PE2017002446A patent/PE20180670A1/es unknown
- 2016-05-20 KR KR1020177036611A patent/KR20180010229A/ko not_active Application Discontinuation
- 2016-05-20 RU RU2017144467A patent/RU2733754C2/ru active
- 2016-05-20 CR CR20170584A patent/CR20170584A/es unknown
- 2016-05-20 IL IL255769A patent/IL255769B2/en unknown
- 2016-05-20 CR CR20200476A patent/CR20200476A/es unknown
- 2016-05-20 AU AU2016264623A patent/AU2016264623B2/en active Active
- 2016-05-20 MX MX2017014700A patent/MX2017014700A/es unknown
- 2016-05-20 EP EP16732018.3A patent/EP3297660A2/en active Pending
- 2016-05-20 MY MYPI2017001689A patent/MY190974A/en unknown
- 2016-05-20 IL IL302102A patent/IL302102A/en unknown
- 2016-05-20 US US15/575,328 patent/US10835585B2/en active Active
- 2016-05-20 JP JP2017560196A patent/JP6913032B2/ja active Active
- 2016-05-20 CR CR20230191A patent/CR20230191A/es unknown
- 2016-05-20 CA CA2986235A patent/CA2986235A1/en active Pending
- 2016-05-20 TW TW112105056A patent/TW202346325A/zh unknown
- 2016-05-20 IL IL294183A patent/IL294183B2/en unknown
- 2016-05-20 CN CN202211239802.9A patent/CN116196401A/zh active Pending
- 2016-05-20 CN CN201680042436.4A patent/CN108025048B/zh active Active
-
2017
- 2017-11-16 MX MX2023005122A patent/MX2023005122A/es unknown
- 2017-11-20 CL CL2017002945A patent/CL2017002945A1/es unknown
- 2017-12-13 CO CONC2017/0012835A patent/CO2017012835A2/es unknown
- 2017-12-15 PH PH12017502321A patent/PH12017502321A1/en unknown
- 2017-12-20 EC ECIEPI201784137A patent/ECSP17084137A/es unknown
-
2018
- 2018-08-15 HK HK18110507.5A patent/HK1251148A1/zh unknown
- 2018-09-07 HK HK18111576.9A patent/HK1252267A1/zh unknown
-
2020
- 2020-04-27 US US16/859,252 patent/US20200368337A1/en active Pending
-
2021
- 2021-07-09 JP JP2021114423A patent/JP7282834B2/ja active Active
-
2022
- 2022-09-28 AU AU2022241521A patent/AU2022241521A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081513A patent/JP2023103405A/ja active Pending
- 2023-08-16 CL CL2023002421A patent/CL2023002421A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023002421A1 (es) | Neoantígenos compartidos | |
CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
CY1124224T1 (el) | Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων | |
CY1123902T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι tου καρκινου του οισοφαγου και αλλων καρκινων | |
CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
CY1122465T1 (el) | Συνδυασμενη φαρμακευτικη συνθεση | |
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
CO2019010524A2 (es) | Plataforma de identificación de péptidos inmunogénicos basada en población | |
CY1123635T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου των ωοθηκων και αλλων καρκινων | |
CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
CR20170138A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
CY1124950T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ | |
EA201790239A1 (ru) | Молекула-носитель для антигенов | |
CR20190209A (es) | Inmunoglobulinas y usos de estas | |
CL2019002944A1 (es) | Nuevos péptidos y combinación de péptidos para el uso de la inmunoterapia contra varios tipos de cáncer. (divisional solicitud 201801533) | |
CY1124813T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου | |
CY1124038T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων και ικριωματων αυτων για χρηση στην ανοσοθεραπεια εναντι του ορθοκολικου καρκινου (crc) και αλλων καρκινων | |
UY36344A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
TH168784A (es) |